Sudeep Pharma Share Price Slide 6% After Q2 FY26 Earnings Profit, Margins Weaken

Sudeep Pharma share price came under pressure on Monday, December 22, 2025, after the company reported a weak set of results for the September quarter (Q2FY26). The stock slipped as much as 6.03% to an intraday low of ₹644.90.

At around 9:25 am, the shares were trading nearly 4% lower at ₹658.90, even as the broader market remained positive.

Sudeep Sharma Q2FY26 Financial Performance

The fall in the stock was mainly due to a decline in profitability.

• Net profit: Dropped 4% year-on-year to ₹46.8 crore in Q2FY26 from ₹48.7 crore in Q2FY25
• Revenue: Rose to ₹162.7 crore from ₹148.8 crore a year ago, showing healthy topline growth
• EBITDA: Almost flat at ₹65.6 crore compared to ₹65.3 crore last year
• EBITDA margin: Fell sharply to 38% from 43.4% in Q2FY25
• EPS: Declined to ₹4.20 from ₹4.49

The sharp drop in margins despite higher revenue worried investors, leading to selling pressure.

Sudeep Sharma Share price movement

As of 9:34 am, Sudeep Pharma share price was trading at ₹665.80, down ₹21.40 or 3.11%. The stock remains well below its recent highs.

About Sudeep Pharma

Founded in 1989, Sudeep Pharma is a global player in mineral-based excipients, speciality nutrition ingredients, and food-grade minerals. The company supplies calcium, iron, magnesium, and zinc derivatives to pharma, nutraceutical, and food companies across more than 100 countries.

Read More: HDFC Bank, RIL and Infosys Lead ICICI Prudential Mutual Fund’s Top Picks for November 2025.

IPO background

Sudeep Pharma made a strong market debut on November 28, 2025. The shares listed at a premium of over 23% to the IPO price of ₹593, reflecting strong investor interest at the time.

Conclusion

Sudeep Pharma’s sharp fall today was driven by lower profit and a significant drop in margins, which overshadowed revenue growth. Investors will now watch whether margins improve in the coming quarters to support the stock’s valuation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.